Adams, David S.
Antibody-drug conjugates (ADCs) are a type of targeted therapy for killing cancer cells that are composed of an antibody directed against a tumor antigen linked to a potent cytotoxic drug that kills the cell. ADCs have great potential, and in some cases have been shown to cause complete cancer remissions. Although the targeting idea appears to be simple, to date only two ADC drugs have received FDA approval. The goal of this IQP project was to evaluate ADC technology by assessing its technical and regulatory problems in order to help determine the obstacles for gaining approval. We conclude that the approved ADCs had well-chosen target antigens and years of research prior to approval. We recommend that ADC research be continued to identify other adequate target antigens.
Worcester Polytechnic Institute
Interactive Qualifying Project
All authors have granted to WPI a nonexclusive royalty-free license to distribute copies of the work, subject to other agreements. Copyright is held by the author or authors, with all rights reserved, unless otherwise noted.
Biology and Biotechnology